OncLive® On Air

OncLive® On Air

Health EN ↓ 576 episodes

In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.

Be sure to visit the podcast's website and support the creator: www.onclive.com

Author

OncLive® On Air

Category

Health

Podcast website

www.onclive.com

Latest episode

Nov 13, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android almost 10M downloads · 4.7+ rating iOS soon

Episodes

S18 Ep46: Unpacking Data and Upcoming Developments for Olverembatinib in CML 29.09.2026

In today’s episode, we spoke with Elias Jabbour, MD, and Dennis Kim, MD. Dr Jabbour is a professor of Leukemia at The University of Texas MD Anderson Cancer Center in Houston. Dr Kim is an associate professor at the Institute of Medical Science at the University of Toronto in Canada. In our exclusive interview, Drs Jabbour and Kim discussed the third-generation TKI olverembatinib (HQP1351), how it...

S18 Ep45: Advancing Targeted Therapy in HR+/HER2– Metastatic Breast Cancer: Integrating Next-Generation Endocrine and PAM-Pathway Strategies Into Practice 28.09.2026

Highlights from the PER® CME activity "Advancing Targeted Therapy in HR+/HER2– Metastatic Breast Cancer: Integrating Next-Generation Endocrine and PAM-Pathway Strategies Into Practice " — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below. In this podcast, experts Joyce O’Shaughnessy, MD, Sarat Chandarlapaty, MD, PhD, Mi...

S18 Ep44: Exploring the FDA Approval of Optune Pax and What It Means for Locally Advanced Pancreatic Cancer 28.09.2026

In today’s episode, we spoke with Philip A. Philip, MD. Dr Philip is the director of Gastrointestinal Oncology, co-director of the Pancreatic Cancer Center, and medical director of Research and Clinical Care Integration at the Henry Ford Cancer Institute in Detroit, Michigan. In our exclusive interview, Dr Philip discussed the February 2026 FDA approval of Optune Pax for lo cally advanced pancreat...

S18 Ep43: Neoadjuvant Immunotherapy and Short Treatment Courses Drive Paradigm Shifts in CRC Management 25.09.2026

In this episode of Oncology Unplugged , host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Pashtoon Kasi, MD, MS, the medical director of GI Medical Oncology, the Rad Family Chair in Gastrointestinal Oncology, and an associate clinical professor in the Department of Medical Oncology & Therapeutics Research at City of Hope Orange Count...

S18 Ep42: Breaking Down the FDA Approval of Zanidatamab-Based Regimens in HER2+ Gastric Cancer 24.09.2026

In today’s episode, we spoke with Nataliya Uboha, MD, PhD. Dr Uboha is an associate professor and researcher in the Department of Medicine at the University of Wisconsin School of Medicine in Madison. In our exclusive interview, Dr Uboha discussed the August 2026 FDA approval of zanidatamab (Ziihera)-based regimens for first-line HER2-positive locally advanced or metastatic gastric cancer , and un...

S18 Ep41: Recent Data Readouts Help Untangle HER2 Overexpression and Mutation Implications in NSCLC 24.09.2026

In today’s episode, Narjust Florez, MD, and Jonathan Wesley Riess, MD, MS, hosted a discussion about the distinction between HER2 overexpression and HER2 mutations in non–small cell lung cancer (NSCLC). Dr Florez is the associate medical director of the Cancer Care Access Program and a physician at Dana-Farber Cancer Institute, as well as an assistant professor of medicine and a faculty member at...

S18 Ep40: INCB161734 Holds Potential Significance for KRAS G12D–Mutated mPDAC Management 23.09.2026

In today’s episode, we spoke with Davide Melisi, MD, PhD. Dr Melisi is an associate professor of medical oncology at the University of Verona in Italy. In our exclusive interview, Dr Melisi discussed the investigational oral KRAS G12D inhibitor INCB161734, its mechanism of action, what early data have shown with the agent, and the aims of the ongoing phase 3 DAWN-303 trial (NCT07522073) evaluating...

S18 Ep39: Pancreatic Cancer Experts Map Treatment Sequencing With Liposomal Irinotecan and Beyond 21.09.2026

In today’s episode, we spoke with Raji Shameem, MD, and Shubham Pant, MD, MBBS. Dr Shameem is a clinical assistant professor of medicine at the Orlando College of Osteopathic Medicine, an assistant professor of Medicine at the University of Central Florida, and a physician at Orlando Health. Dr Pant is a professor in the Department of Gastrointestinal Medical Oncology and the Department of Investi...

S18 Ep34: Integrating Precision Pathways in HER2+ Gastroesophageal Adenocarcinoma—Testing, Treatment, and Supportive Care 21.09.2026

Highlights from the PER® CME activity "SimulatED: Integrating Precision Pathways in HER2+ Gastroesophageal Adenocarcinoma — Testing, Treatment, and Supportive Care" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below. In this podcast, experts Geoffrey Y. Ku, MD, and Sunnie Kim, MD, discuss essential biomarker testing fo...

S18 Ep38: Fast-Moving Treatment Advances Shape B-Cell Lymphoma Care 17.09.2026

In this episode of Oncology Unplugged , host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Joshua Brody, MD, the director of the Lymphoma Immunotherapy Program at the Mount Sinai Tisch Cancer Center and a faculty member of the Icahn Genomics Institute in New York, New York. Their discussion centered on the rapidly evolving treatment lands...

S18 Ep37: Metastatic Non-Small Cell Lung Cancer 2026 UPDATE 14.09.2026

Two Onc Docs , hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematolog...

S18 Ep36: Precision Immunotherapy, PET-Adapted Regimens, and Novel Targets Are Redefining Hodgkin Lymphoma Care: With Chandler Park, MD; Joshua Brody, MD 14.09.2026

In this episode of Oncology Unplugged , host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Joshua Brody, MD, the director of the Lymphoma Immunotherapy Program at the Mount Sinai Tisch Cancer Center and a faculty member of the Icahn Genomics Institute in New York, New York. Their discussion centered on the evolving frontline and relapsed...

S18 Ep35: The ADC Revolution in Metastatic Breast Cancer: Redefining Treatment Selection and Sequencing 11.09.2026

Highlights from the PER® CME activity "The ADC Revolution in Metastatic Breast Cancer: Redefining Treatment Selection and Sequencing" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below. In this podcast, experts Seth A. Wander, MD, PhD, Reshma L. Mahtani, DO, and Shanu Modi, MD, review pivotal data regarding the use of...

S18 Ep33: Current Approaches and Future Directions for Early-Stage TNBC 04.09.2026

Highlights from the PER® CME activity "Current Approaches and Future Directions for Early-Stage TNBC" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below. In this podcast, experts Nour Abuhadra, MD, and Antonio Giordano, MD, PhD, discuss the emerging role of antibody-drug conjugates (ADCs) in early-stage triple-negative...

S18 Ep32: Non–Small Cell Lung Cancer 2026 UPDATE 31.08.2026

Two Onc Docs , hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematolog...

S18 Ep31: FDA Approval Insights: Integrating RP1 Plus Nivolumab Into Post–PD-1 Melanoma Practice: With Michael K. Wong, MD, PhD, FRPC 28.08.2026

In today's episode, we spoke with Michael K. Wong, MD, PhD, FRPC. Dr Wong is a physician at Roswell Park Comprehensive Cancer Center in Buffalo, New York. In our exclusive interview, Dr Wong discussed the significance of the FDA’s accelerated approval of vusolimogene oderparepvec-wtpg (Tudriqev; RP1) in combination with nivolumab (Opdivo) for adult patients with unresectable advanced cutaneous mel...

S18 Ep31: Immunotherapy Decision-Making in CSCC Sits at the Intersection of Efficacy and Comorbidity: With Eric D. Whitman, MD; and Francis Paul Worden, MD 28.08.2026

Eric D. Whitman, MD, and Francis Paul Worden, MD, discuss the integration of immunotherapy into the cutaneous squamous cell carcinoma (CSCC) treatment paradigm and key considerations for navigating treatment selection for this patient population. The pair also highlight strategies to maximize efficacy and minimize toxicity with immunotherapy-based approaches.

S18 Ep30: FDA Approval Insights: Iberdomide-Based Therapy Adds Another Option for R/R Myeloma: With Sagar Lonial, MD, FACP, FASCO 27.08.2026

In today’s episode, we welcomed Sagar Lonial, MD, FACP, FASCO, to discuss the significance of the August 2026 FDA accelerated approval of iberdomide (Zenbexus) plus daratumumab and hyaluronidase-fihj (Darzalex Faspro) and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor...

S18 Ep29: 𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment 24.08.2026

Highlights from the PER® CME activity " MET Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below. In this podcast, experts Jonathan Goldman, MD; Sanja Dacic, MD, PhD; Deborah Doroshow, MD, PhD; and Anne S. Tsao, MD, MBA,...

S18 Ep28: Pancreatic Cancer Treatment Advances Call for a Renewed Focus on the Role of Liposomal Irinotecan: With Jennifer B. Valerin, MD, PhD 20.08.2026

In today’s episode, we spoke with Jennifer B. Valerin, MD, PhD. Dr Valerin is an assistant professor in the Divisions of Hematology and Oncology and Medicine at the University of California, Irvine School of Medicine. In our exclusive interview, Dr Valerin discussed the clinical role of liposomal irinotecan (Onivyde) in pancreatic cancer management, factors influencing the decision to use liposoma...

S18 Ep27: Key Considerations for Health Equity and Patient-Centered Care in TNBC 17.08.2026

Highlights from the PER® CME activity "Key Considerations for Health Equity and Patient-Centered Care in TNBC" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below. In this podcast, experts Aditya Bardia, MD, MPH, FASCO, and Kathryn E. Post, PhD, ANP-BC, discuss key drivers of disparities in outcomes for triple-negative...

S18 Ep26: FDA Approval Insights: Gedatolisib Plus Fulvestrant ± Palbociclib for HR+, HER2-Negative, PIK3CA Wild-Type Advanced Breast Cancer: With Adam M. Brufsky, MD, PhD 14.08.2026

In today’s episode, we spoke with Adam M. Brufsky, MD, PhD, about the FDA approval of gedatolisib (Revtorpyk) plus fulvestrant (Faslodex), with or without palbociclib (Ibrance), for the treatment of adult patients with hormone receptor–positive, HER2-negative advanced breast cancer without a PIK3CA mutation following progression on or after treatment with 1 or more lines of endocrine therapy in th...

S18 Ep25: Greater Flexibility and Improved QOL Represent Key Potential Benefits With Liquid TKI Formulations: With Jonathan Trent, MD, PhD 07.08.2026

In today’s episode, we spoke with Jonathan Trent, MD, PhD, a professor in the Department of Medicine in the Division of Medical Oncology, associate director of Clinical Research, and the director of the Sarcoma Medical Research Program at the University of Miami Miller School of Medicine in Florida. In our exclusive interview, Dr Trent discussed currently approved TKIs for patients with gastrointe...

S18 Ep24: Precision Oncology, Bispecific Antibodies, and Next-Generation Targeted Therapies Are Reshaping NSCLC Care: With Chandler Park, MD; Stephen V. Liu, MD 04.08.2026

In this episode of Oncology Unplugged , host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Stephen V. Liu, MD, the division chief of Hematology Oncology at MedStar Georgetown University Hospital, part of the MedStar Georgetown Cancer Institute, in Washington, DC. Their discussion centered on the continued evolution of precision medicine i...

S18 Ep23: From Trials to the Clinic: Incorporating New Advances in Metastatic TNBC 03.08.2026

Highlights from the PER® CME activity "From Trials to the Clinic ‒ Incorporating New Advances in Metastatic TNBC" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below. In this podcast, experts William Gradishar, MD, FASCO, FACP; and Kamel Abou Hussein, MD; discuss optimizing first-line treatment selection in metastatic t...

Listen to the OncLive® On Air podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.